GlassScriptPhysician profile
Noelle H Simms
NPI 1760027528
$17,081.37
in general payments reported to CMS, 2019-2025
36 companies · $7,088 in 2025
The $7,088 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,566 · 2022: $1,885 · 2023: $4,255 · 2024: $2,288 · 2025: $7,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,790 · Consulting Fee: $3,425 · Travel and Lodging: $2,398 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,789.87 |
| Consulting Fee | $3,425.00 |
| Travel and Lodging | $2,397.88 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $5,186.47 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Cvrx, INC. | $3,601.21 | 2023-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $1,551.42 | 2024-2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $731.16 | 2021-2025 | |
| Medtronic, INC. | $680.99 | 2021-2025 | Linq II |
| Merck Sharp & Dohme LLC | $611.31 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $529.58 | 2021-2025 | Wainua, Farxiga, Brilinta |
| United Therapeutics Corporation | $385.34 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Abiomed | $381.93 | 2021-2024 | Impella |
| Abbott Laboratories | $359.78 | 2025 | Cardiomems, Triclip |
| Bayer Healthcare Pharmaceuticals INC. | $355.48 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $323.81 | 2022-2025 | Lifevest |
| Scpharmaceuticals INC. | $317.12 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $283.57 | 2021-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $280.43 | 2022-2025 | Ozempic, Rybelsus |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $261.98 | 2024-2025 | Amvuttra |
| Pfizer INC. | $227.96 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.42 | 2021-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $172.18 | 2023-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $70.99 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $64.94 | 2025 | Attruby |
| Philips North America LLC | $59.21 | 2023-2024 | (5044) Mcot |
| Daxor Corporation | $53.02 | 2024 | Bva-100 |
| Boston Scientific Corporation | $50.95 | 2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Daiichi Sankyo INC. | $43.12 | 2022-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $41.63 | 2022-2023 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $38.77 | 2023 | Arcalyst |
| Biosense Webster, INC. | $31.38 | 2022 | |
| Amgen INC. | $28.68 | 2024-2025 | Repatha |
| Sandoz INC. | $25.60 | 2023 | Treprostinil |
| Endotronix, INC. | $23.03 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Sanofi-Aventis U.S. LLC | $21.76 | 2021 | |
| Altathera Pharmaceuticals LLC | $16.72 | 2025 | Sotalol Hydrochloride |
| Baxter Healthcare | $14.59 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $14.38 | 2024 | |
| Celgene Corporation | $13.46 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.